Lastly, as microglia activation precedes MS lesion formation,47 and CD200 suppresses activation of microglia, activation of the CD200–CD200R pathway could be an interesting therapeutic target to decrease overall microglia activation and may limit the formation of new lesions. Here, CD200 is linked to myeloid sarcoma.